Other languages Tryp Therapeutics Inc. OTC Markets

Equities

TRYPF

CA89854F1062

Market Closed - OTC Markets Other stock markets 02:06:05 2024-04-29 pm EDT			5-day change	1st Jan Change
0.0476 ^USD	-2.76%		+32.50%	+39.88%

Mar. 08	Tryp Therapeutics Inc. announced that it has received AUD 3.39 million in funding	CI
Feb. 05	Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	Feb. 05
Tryp Therapeutics Inc. Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at the University of Michigan	Jan. 04
Tryp Therapeutics Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Dec. 29
Tryp Therapeutics Inc. acquired Tryptamine Therapeutics Australia PTY LTD.	Dec. 28
Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023	23-08-03
Tryp Therapeutics Inc. Announces the Passing of David Tousley, Director	23-08-02
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2A Clinical Trial in Patients with IBS At Massachusetts General Hospital	23-08-01
Tryp Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-31
Tryp Therapeutics Submits Investigational New Drug Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital	23-05-24
Tryp Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-28
Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial At Massachusetts General Hospital	23-04-04
Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-25
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder with Psilocybin-Assisted Psychotherapy	23-01-05
Tryp Therapeutics Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	22-12-13
Tryp Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	22-12-12
Tryp Therapeutics Inc. Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin	22-10-03
Tryp Therapeutics, Inc. Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803	22-09-26
Tryp Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	22-07-28
Tryp Therapeutics Inc. Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment	22-06-29
Tryp Therapeutics Appoints Sid Taubenfeld as Chief Operating Officer	22-06-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tryp Therapeutics Inc. OTC Markets

Equities

TRYPF

CA89854F1062

Other languages

Filters